Global Z-drugs Market
Introduction
Nonbenzodiazepines, commonly
referred as Z-drugs, are a widely prescribed class of psychoactive drugs for
the treatment of different types of sleep disorders, particularly insomnia,
which affects millions of people across the world. These drugs have similar
effects as benzodiazepines by potentiating GABA (gamma-aminobutyric acid)
activity in the body.
Read Report Overview - https://www.transparencymarketresearch.com/z-drugs-market.html
Global Z-drugs Market -
Competitive Landscape
Teva Pharmaceutical Industries
Ltd., Sanofi, and Pfizer, Inc. are the major players operating in the global
Z-drugs market. New product development and focus on emerging markets where the
prevalence of insomnia is high are the strategies adopted by these players to
increase market share.
Teva Pharmaceutical
Industries, Ltd.
Teva Pharmaceutical Industries
Ltd. is a key manufacturer of generic medicines and a recognized leader in
innovative and specialty pharmaceuticals across the globe. The company delivers
high quality and patient-centric health care solutions. It has a broad generics
portfolio, with more than 1,000 molecules in nearly every therapeutic area. It
continues to evaluate opportunities for joint ventures, collaborations, and
other activities that support growth. Teva Pharmaceutical Industries focuses on
establishing leadership position in its core therapeutic areas of respiratory
(including asthma & COPD) and CNS through business development initiatives
such as acquisition of Labrys Biologics in 2014 and Auspex Pharmaceuticals,
Inc. in 2015.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=71355
Pfizer, Inc.
Pfizer, Inc. operates through two
business segments: Pfizer Innovative Health and Pfizer Essential Health. The
company has been issued 129 patents in the U.S. and 1,807 in the rest of the
world for its products. It offers products in multiple therapeutic areas such
as endocrinology, neurology, immunology, oncology, HIV, rare diseases, and
hematology in more than 125 countries. Pfizer, Inc. has developed a strong
supply chain network, which is directly responsible for addressing the
patients’ needs. With technological advancements, the company tracks movement
of products throughout the entire supply chain.
Sanofi
Sanofi is a global provider of
health care solutions. The company has broad product portfolio that caters to
areas such as rare diseases, multiple sclerosis, oncology, immunology,
infectious diseases, diabetes, cardiovascular diseases, vaccines, and consumer
health care. Sanofi focuses on acquisitions, in-licensing, and collaborations
with key players in the market to reinforce its product pipeline. The company
emphasizes on strategic reshaping of the product portfolio in order to
strengthen its position in developed and
emerging markets.
Request for Analysis of COVID-19 Impact on Z-drugs Market
- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=71355
Global Z-drugs Market Dynamics
Large Patient Pool of Sleep
Disorder Drives Demand for Z-drugs
Sleep disorder is a health
concern for a larger percentage of the general population of the world.
According to the Journal of Family Medicine and Primary Care, prevalence of sleep
disorder is 10% to 30% of the global population, and insomnia in particular is
on the rise. It is common in older adults, women, and people with medical and
mental ill health. Such large population base of sleep disorder, especially
insomnia, drives demand for Z-drugs.
Major Side Effects of Z-drugs
to Hamper Market
Users of nonbenzodiazepines have
reportedly experienced side effects such as short-term memory loss,
sleepwalking, sleep driving, dizziness, headache, back pain, and rashes. This
induces them to stop taking the drugs for long-term treatment, which in turn
hampers sales of the drugs.
Pre Book Z-drugs Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=71355<ype=S
North America Dominated Global
Z-drugs Market in 2018
According to the National Sleep
Foundation, insomnia is the most common sleep disorder in the U.S. Moreover,
around 40 million people in North America are affected by insomnia each year.
The foundation also stated that prevalence of insomnia has increased among
women and older adults in the region. Availability of drugs, high awareness
about the effects of sleep disorder, and high prevalence of sleep disorders drive
demand for Z-drugs in North America.
More Trending Reports by Transparency Market Research –
Shizophrenia Drugs Market: https://www.prnewswire.com/news-releases/patent-expiry-of-notable-drugs-to-open-up-plethora-of-opportunities-for-key-players-in-global-schizophrenia-drugs-market-transparency-market-research-300998435.html
Ultraviolet Germicidal Irradiation Market: https://www.biospace.com/article/ultraviolet-germicidal-irradiation-market-rapidly-depleting-fresh-water-source-to-support-market-demand/
About Us
Transparency Market Research is a
global market intelligence company providing global business information reports
and services. Our exclusive blend of quantitative forecasting and trends
analysis provides forward-looking insight for several decision makers. Our
experienced team of analysts, researchers, and consultants use proprietary data
sources and various tools and techniques to gather and analyze information.
Our data repository is
continuously updated and revised by a team of research experts so that it
always reflects latest trends and information. With a broad research and
analysis capability, Transparency Market Research employs rigorous primary and
secondary research techniques in developing distinctive data sets and research
material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free:
866-552-3453
